DSP Business Cycle Fund Direct (G) : NFO Details
This pharma stock is buzzing on the bourses today
Last Updated: 27th October 2022 - 02:51 pm
In the last five trading sessions, the stock surged more than 7%.
On October 27, the market is trading green. At 12:48 pm, the S&P BSE Sensex is trading at 59,589.21, up 0.08%, while NIFTY50 is 0.13% up on the day and trading at 17,679.55. About sectoral performance, Metal and Consumer Durables are among the top gainers, while IT is the top loser for the day. Regarding stock-specific action, Jubilant Pharmova Ltd is among the top gainers.
Shares of Jubilant Pharmova Ltd have surged 2.55% and are trading at Rs 345.8, as of 12:50 pm. The stock opened at Rs 337.2 and so far, has made an intraday high and low of Rs 356.05 and Rs 337.2, respectively.
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments Pharmaceuticals, Drug Discovery & Development Solutions and Proprietary Novel Drugs. On October 22, the company announced its latest September quarter results.
For Q1FY23, its consolidated net revenue from operations decreased by 3% YoY and came in at Rs 1584.74 crore as against Rs 1213 crore a year ago, EBITDA declined by 35.57% YoY to Rs 218 crore in Q1FY23 from Rs 339.50 crore a year ago. PAT stood at Rs 7.58 crore compared to Rs 144.03 crore a year ago, a decline of almost 95 % on a YoY basis. In Q1FY23, EBIDTA margins reduced by 625 basis points YoY from 20.75% to 14.5%. The PAT margin remained poor at 0.47% in Q1FY23.
About the shareholding pattern, 50.67% of the company’s stake is owned by the promoter, 23.06% by FIIs, 1.6% by DIIs, and the rest 24.59% by the non-institutional investors.
The company has a market capitalisation of Rs 5514 crore and belongs to BSE group A. It is trading at a PE multiple of 68.7x. The scrip has a 52-week high and low of Rs 356.05 and Rs 337.2, respectively.
Trending on 5paisa
Discover more of what matters to you.
Indian Market Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.